BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 10739388)

  • 1. Cellular degradation of free and inhibitor-bound tissue-type plasminogen activator--requirement for a co-receptor?
    Camani C; Gavin O; Kruithof EK
    Thromb Haemost; 2000 Feb; 83(2):290-6. PubMed ID: 10739388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator.
    Horn IR; van den Berg BM; Moestrup SK; Pannekoek H; van Zonneveld AJ
    Thromb Haemost; 1998 Nov; 80(5):822-8. PubMed ID: 9843178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the interaction of a complex of tissue-type plasminogen activator and plasminogen activator inhibitor type 1 with rat liver cells.
    Kuiper J; Otter M; Voorschuur AH; van Zonneveld AJ; Rijken DC; van Berkel TJ
    Thromb Haemost; 1995 Nov; 74(5):1298-304. PubMed ID: 8607113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pregnancy zone protein-tissue-type plasminogen activator complexes bind to low-density lipoprotein receptor-related protein (LRP).
    Sánchez MC; Chiabrando GA; Vides MA
    Arch Biochem Biophys; 2001 May; 389(2):218-22. PubMed ID: 11339811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of the low-density lipoprotein receptor-related protein (LRP) in the plasma clearance and liver uptake of recombinant single-chain urokinase-type plasminogen activator in rats.
    van der Kaaden ME; Rijken DC; Kruijt JK; van Berkel TJ; Kuiper J
    Thromb Haemost; 1997 Apr; 77(4):710-7. PubMed ID: 9134648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
    Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
    J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential endocytosis of tissue plasminogen activator by serpins PAI-1 and PAI-2 on human peripheral blood monocytes.
    Lee JA; Croucher DR; Ranson M
    Thromb Haemost; 2010 Dec; 104(6):1133-42. PubMed ID: 20838737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrinolytic activity of human mesothelial cells is counteracted by rapid uptake of tissue-type plasminogen activator.
    Sitter T; Toet K; Quax P; Kooistra T
    Kidney Int; 1999 Jan; 55(1):120-9. PubMed ID: 9893120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
    Skeldal S; Larsen JV; Pedersen KE; Petersen HH; Egelund R; Christensen A; Jensen JK; Gliemann J; Andreasen PA
    FEBS J; 2006 Nov; 273(22):5143-59. PubMed ID: 17042782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of tissue plasminogen activator and plasminogen activator inhibitor-1 by transforming growth factor-beta in human retinal glial cells.
    Schacke W; Beck KF; Pfeilschifter J; Koch F; Hattenbach LO
    Invest Ophthalmol Vis Sci; 2002 Aug; 43(8):2799-805. PubMed ID: 12147618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human Co115 colon carcinoma cells potentiate the degradation of laminin mediated by tissue-type plasminogen activator.
    Tran-Thang C; Vouillamoz D; Kruithof EK; Sordat B
    J Cell Physiol; 1994 Nov; 161(2):285-92. PubMed ID: 7962113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clearance receptors for tissue-type plasminogen activator.
    Camani C; Kruithof EK
    Int J Hematol; 1994 Aug; 60(2):97-109. PubMed ID: 7948967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma.
    Hofmann R; Lehmer A; Buresch M; Hartung R; Ulm K
    Cancer; 1996 Aug; 78(3):487-92. PubMed ID: 8697395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the binding of pro-urokinase and urokinase-plasminogen activator inhibitor-1 complex to the low density lipoprotein receptor-related protein using a Fab fragment selected from a phage-displayed Fab library.
    Horn IR; Moestrup SK; van den Berg BM; Pannekoek H; Nielsen MS; van Zonneveld AJ
    J Biol Chem; 1995 May; 270(20):11770-5. PubMed ID: 7538122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of oxidative stress on the expression of t-PA, u-PA, u-PAR, and PAI-1 in endothelial cells.
    Oszajca K; Bieniasz M; Brown G; Swiatkowska M; Bartkowiak J; Szemraj J
    Biochem Cell Biol; 2008 Dec; 86(6):477-86. PubMed ID: 19088796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparin selectively inhibits synthesis of tissue type plasminogen activator and matrix deposition of plasminogen activator inhibitor 1 by human mesangial cells.
    Hagège J; Delarue F; Peraldi MN; Sraer JD; Rondeau E
    Lab Invest; 1994 Dec; 71(6):828-37. PubMed ID: 7807964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptional regulation of tissue- and urokinase-type plasminogen activator genes by thrombin in human fetal lung fibroblasts.
    Hayakawa Y; Tazawa S; Ishikawa T; Niiya K; Sakuragawa N
    Thromb Haemost; 1995 Aug; 74(2):704-10. PubMed ID: 8585010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor-mediated endocytosis of tissue-type plasminogen activator by low density lipoprotein receptor-related protein on human hepatoma HepG2 cells.
    Bu G; Maksymovitch EA; Schwartz AL
    J Biol Chem; 1993 Jun; 268(17):13002-9. PubMed ID: 8389767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of plasminogen activators and plasminogen activator inhibitor 1 in dedifferentiated chondrosarcoma.
    Häckel C; Czerniak B; Ayala AG; Radig K; Roessner A
    Cancer; 1997 Jan; 79(1):53-8. PubMed ID: 8988726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of plasminogen activators and plasminogen activator inhibitors in cutaneous melanomas of transgenic melanoma-susceptible mice.
    de Vries TJ; Kitson JL; Silvers WK; Mintz B
    Cancer Res; 1995 Oct; 55(20):4681-7. PubMed ID: 7553649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.